Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C57H110O6 |
| Molecular Weight | 891.4797 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC
InChI
InChIKey=DCXXMTOCNZCJGO-UHFFFAOYSA-N
InChI=1S/C57H110O6/c1-4-7-10-13-16-19-22-25-28-31-34-37-40-43-46-49-55(58)61-52-54(63-57(60)51-48-45-42-39-36-33-30-27-24-21-18-15-12-9-6-3)53-62-56(59)50-47-44-41-38-35-32-29-26-23-20-17-14-11-8-5-2/h54H,4-53H2,1-3H3
| Molecular Formula | C57H110O6 |
| Molecular Weight | 891.4797 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Tristearin is a chemical compound from the group of simple triglycerides. All three hydroxy groups of glycerol are esterified with stearic acid. It was shown that in tristearin treated human umbilical vein smooth muscle cells (HUVSMCs), the saturated fatty acid content was increased, and the compositions of polyunsaturated fatty acid (PUFA) and monounsaturated fatty acid were decreased significantly. Tristearin had significant promotion effects on the proliferation of HUVSMCs induced by oxidized‐LDL. Tristearin is a triacylglycerol commonly found in dietary fats. It increases serum cholesterol levels in rats. Tristearin is also used to form the lipid matrices of solid lipid nanoparticles. Formulations containing tristearin are used in cosmetic products to condition skin and as thickening agents.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Lipase catalyzed interesterification of palm stearin and rice bran oil blends for preparation of zero trans shortening with bioactive phytochemicals. | 2008-07 |
|
| Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. | 2008-02-04 |
|
| Biochemical structure of Calendula officinalis. | 2007-10-09 |
|
| Pharmacogenetic study of cholesteryl ester transfer protein gene and simvastatin treatment in hypercholesterolaemic subjects. | 2007-10 |
|
| Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy. | 2007-09 |
|
| Incoherent quasielastic neutron scattering study on the polymorphism of tristearin: dynamical properties of hydrocarbon chains. | 2007-08-23 |
|
| Biodegradation kinetics and toxicity of vegetable oil triacylglycerols under aerobic conditions. | 2007-08 |
|
| New insight into the role of polyethylene glycol acting as protein release modifier in lipidic implants. | 2007-08 |
|
| Effects of stereospecific positioning of fatty acids in triacylglycerol structures in native and randomized fats: a review of their nutritional implications. | 2007-07-12 |
|
| Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. | 2007-07-10 |
|
| Development of spherical iron(II) sulfate heptahydrate-containing solid particles with sustained drug release. | 2007-05 |
|
| Mechanisms controlling protein release from lipidic implants: effects of PEG addition. | 2007-04-02 |
|
| Abnormal hepatobiliary and circulating lipid metabolism in the Long-Evans Cinnamon rat model of Wilson's disease. | 2007-03-27 |
|
| Acidolysis of tristearin with selected long-chain fatty acids. | 2007-03-07 |
|
| In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model. | 2007-03 |
|
| Defective glycerol metabolism in aquaporin 9 (AQP9) knockout mice. | 2007-02-27 |
|
| Stearic acid-rich interesterified fat and trans-rich fat raise the LDL/HDL ratio and plasma glucose relative to palm olein in humans. | 2007-01-15 |
|
| Premating isolation is determined by larval rearing substrates in cactophilic Drosophila mojavensis. VII. Effects of larval dietary fatty acids on adult epicuticular hydrocarbons. | 2006-12 |
|
| Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. | 2006-11 |
|
| Low-density lipoproteins generated during an oral fat load in mild hypertriglyceridemic and healthy subjects are smaller, denser, and have an increased low-density lipoprotein receptor binding affinity. | 2006-10 |
|
| Milk fat and primary fractions obtained by dry fractionation 1. Chemical composition and crystallisation properties. | 2006-10 |
|
| Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. | 2006-09-26 |
|
| Encapsulation in lipospheres of the complex between butyl methoxydibenzoylmethane and hydroxypropyl-beta-cyclodextrin. | 2006-08-31 |
|
| NIR spectroscopy-a non-destructive analytical tool for protein quantification within lipid implants. | 2006-08-28 |
|
| Influence of liposphere preparation on butyl-methoxydibenzoylmethane photostability. | 2006-06 |
|
| Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. | 2006-05 |
|
| Propofol formulated with long-/medium-chain triglycerides reduces the pain of injection by target controlled infusion. | 2006-05 |
|
| Enhancement of melatonin photostability by encapsulation in lipospheres. | 2006-03-03 |
|
| Development and characterization of emulsomes for sustained and targeted delivery of an antiviral agent to liver. | 2006-03 |
|
| Glycosylphosphatidylinositol-specific phospholipase D influences triglyceride-rich lipoprotein metabolism. | 2006-03 |
|
| Aluminosis--detection of an almost forgotten disease with HRCT. | 2006-02-17 |
|
| Continuous release of Rh-interferon (alpha-2a from triglyceride implants: storage stability of the dosage forms. | 2006-02 |
|
| Influence of glucose and saturated free-fatty acid mixtures on citric acid and lipid production by Yarrowia lipolytica. | 2006-02 |
|
| PPARalpha activation increases triglyceride mass and adipose differentiation-related protein in hepatocytes. | 2006-02 |
|
| Optimizing efficacy of amphotericin B through nanomodification. | 2006 |
|
| Tamoxifen citrate loaded solid lipid nanoparticles (SLN): preparation, characterization, in vitro drug release, and pharmacokinetic evaluation. | 2006 |
|
| Apolipoprotein A5 and hypertriglyceridemia in Prague hypertriglyceridemic rats. | 2006 |
|
| Monitoring lipase-catalyzed interesterification for bulky fat modification with FT-IR/NIR spectroscopy. | 2005-12-28 |
|
| A secreted lipase encoded by LIP1 is necessary for efficient use of saturated triglyceride lipids in Fusarium graminearum. | 2005-12 |
|
| Fat digestion is required for suppression of ghrelin and stimulation of peptide YY and pancreatic polypeptide secretion by intraduodenal lipid. | 2005-12 |
|
| Characterisation of wax works of art by gas chromatographic procedures. | 2005-10-14 |
|
| Saturated phospholipids promote crystallization but slow down polymorphic transitions in triglyceride nanoparticles. | 2005-10-03 |
|
| Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. | 2005-10-03 |
|
| Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. | 2005-09-16 |
|
| Triacylglycerol-mediated oxidative stress inhibits nitric oxide production in rat isolated hepatocytes. | 2005-09 |
|
| Chronic hyperglycemia, independent of plasma lipid levels, is sufficient for the loss of beta-cell differentiation and secretory function in the db/db mouse model of diabetes. | 2005-09 |
|
| Angiotensin II infusion increases hepatic triglyceride production via its type 2 receptor in rats. | 2005-08 |
|
| Inter-esterified palm products as alternatives to hydrogenation. | 2005 |
|
| Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. | 2005 |
|
| Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? | 2005 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:48:57 GMT 2025
by
admin
on
Mon Mar 31 17:48:57 GMT 2025
|
| Record UNII |
P6OCJ2551R
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Related Record | Type |
|---|
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 172.811
Created by
admin on Mon Mar 31 17:48:57 GMT 2025 , Edited by admin on Mon Mar 31 17:48:57 GMT 2025
|
||
|
NCI_THESAURUS |
C616
Created by
admin on Mon Mar 31 17:48:57 GMT 2025 , Edited by admin on Mon Mar 31 17:48:57 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C77514
Created by
admin on Mon Mar 31 17:48:57 GMT 2025 , Edited by admin on Mon Mar 31 17:48:57 GMT 2025
|
PRIMARY | |||
|
1368872
Created by
admin on Mon Mar 31 17:48:57 GMT 2025 , Edited by admin on Mon Mar 31 17:48:57 GMT 2025
|
PRIMARY | RxNorm | ||
|
P6OCJ2551R
Created by
admin on Mon Mar 31 17:48:57 GMT 2025 , Edited by admin on Mon Mar 31 17:48:57 GMT 2025
|
PRIMARY | |||
|
DTXSID8047503
Created by
admin on Mon Mar 31 17:48:57 GMT 2025 , Edited by admin on Mon Mar 31 17:48:57 GMT 2025
|
PRIMARY | |||
|
209-097-6
Created by
admin on Mon Mar 31 17:48:57 GMT 2025 , Edited by admin on Mon Mar 31 17:48:57 GMT 2025
|
PRIMARY | |||
|
Tristearin
Created by
admin on Mon Mar 31 17:48:57 GMT 2025 , Edited by admin on Mon Mar 31 17:48:57 GMT 2025
|
PRIMARY | |||
|
m11202
Created by
admin on Mon Mar 31 17:48:57 GMT 2025 , Edited by admin on Mon Mar 31 17:48:57 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB42683
Created by
admin on Mon Mar 31 17:48:57 GMT 2025 , Edited by admin on Mon Mar 31 17:48:57 GMT 2025
|
PRIMARY | |||
|
C022618
Created by
admin on Mon Mar 31 17:48:57 GMT 2025 , Edited by admin on Mon Mar 31 17:48:57 GMT 2025
|
PRIMARY | |||
|
11146
Created by
admin on Mon Mar 31 17:48:57 GMT 2025 , Edited by admin on Mon Mar 31 17:48:57 GMT 2025
|
PRIMARY | |||
|
P6OCJ2551R
Created by
admin on Mon Mar 31 17:48:57 GMT 2025 , Edited by admin on Mon Mar 31 17:48:57 GMT 2025
|
PRIMARY | |||
|
45956
Created by
admin on Mon Mar 31 17:48:57 GMT 2025 , Edited by admin on Mon Mar 31 17:48:57 GMT 2025
|
PRIMARY | |||
|
100000130493
Created by
admin on Mon Mar 31 17:48:57 GMT 2025 , Edited by admin on Mon Mar 31 17:48:57 GMT 2025
|
PRIMARY | |||
|
555-43-1
Created by
admin on Mon Mar 31 17:48:57 GMT 2025 , Edited by admin on Mon Mar 31 17:48:57 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SUB_CONCEPT->SUBSTANCE |
